Balyasny Asset Management LLC Cellectis S.A. Transaction History

Balyasny Asset Management LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$2.29 - $4.08 $42,026 - $74,876	18,352 New	18,352 $42,000
Q1 2018 May 15, 2018	SELL	$27.78 - $35.19 $11.4 Million - $14.4 Million	-409,455 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$23.33 - $35.01 $7.38 Million - $11.1 Million	316,455 Added 340.27%	409,455 $11.9 Million
Q3 2017 Nov 14, 2017	BUY	$21.65 - $32.18 $2.01 Million - $2.99 Million	93,000	93,000 $2.65 Million

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.